Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
Robert M Berman1, Michael E Thase2, Madhukar H Trivedi3, James A Hazel4, Sabrina Vogel Marler5, Robert D McQuade6, William Carson7, Ross A Baker8, Ronald N Marcus91Neuroscience Global Clinical Research Bristol-Myers Squibb, Wallingford, CT, USA; 2Department of Psychiatry, University of Pennsylvania...
Guardado en:
Autores principales: | Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d53a80b7fbd44e37b9347a80c49e2718 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008) -
A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
por: Sugawara H, et al.
Publicado: (2016) -
Augmentation with antidepressants in schizophrenia treatment: benefit or risk
por: Mao YM, et al.
Publicado: (2015) -
Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder
por: Jha MK, et al.
Publicado: (2017) -
Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
por: Sicras-Mainar A, et al.
Publicado: (2015)